Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130121 | 0.89 | RECQL (0.53) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10637442 | 0.89 | MEN1 (0.57) | SIGMAR1MEN1KMT2AMCHR1ACHE | |
| SCHEMBL30516673 | 0.82 | SLC18A3 (0.74) | SIGMAR1MEN1KMT2AMCHR1ACHE | |
| SCHEMBL4841620 | 0.81 | CPS1 (0.52) | KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL4839335 | 0.79 | KDM2B (0.50) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL10965600 | 0.75 | POLB (0.67) | MEN1KMT2AACHEPOLB | |
| SCHEMBL4131191 | 0.75 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL6990156 | 0.75 | S1PR5 (0.67) | SIGMAR1MEN1KMT2ASLC18A3KDM4E | |
| SCHEMBL27911661 | 0.74 | SIGMAR1 (0.58) | SIGMAR1ACHESLC18A3 | |
| SCHEMBL7423445 | 0.73 | KDM2B (0.50) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | SIGMAR1 334/4885MEN1 2129/4885KMT2A 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.